Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
PMID: 30364958
2020
Journal of the Pediatric Infectious Diseases Society
Abstract: M184V and Y181C were the most common mutations.
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.
Abstract: The thymidine analogue mutations, M184V/I and the tenofovir-associated DRMs K65R and K70E/Q/G/N/T accounted for 82.9%, 7.3%, and 1.4% of NRTI-associated TDR, respectively.
Result: M184V/I occurred in 20 individuals, comprising 7.3% of NRTI SDRMs.
Epidemiology of human immunodeficiency virus (HIV) drug resistance in HIV patients with virologic failure of first-line therapy in the country of Georgia.
Abstract: All patients had a baseline M184V/I mutation, with 10 (31%) having resistance to TDF; 27 (84%) achieved a VL <200 cp/mL, and 25(78%) had a VL <200 cp/mL at the last reading; 22 (69%) achieved a VL <40 cp/mL.
Abstract: METHODS: This was a single-center chart review of HIV-infected patients receiving daily TDF/FTC plus DRV/r and identified with resistant virus (including, but not limited to, an M184V/I).
Abstract: These retrospective data suggest that despite the presence of an M184V/I, this combination may be an option in patients seeking a once-daily ARV therapy to improve adherence.
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T).
PMID: 30103267
2019
Chemical biology & drug design
Abstract: Mutations at HIV-1 reverse transcriptase (RT) codon 184 such as M184V confer resistance to two nucleos(t)ide RT inhibitors (NRTI), lamivudine (3TC) and emtricitabine (FTC).
Sexual intermingling of Arab and Jewish MSM in Israel: results of a molecular epidemiology study.
Abstract: Overall, 13.1% (66/502) had TDRM; reverse transcriptase-K103N/S, M184 V, T215S and protease-L90M were the most common.
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
PMID: 30380053
2019
The Journal of antimicrobial chemotherapy
Result: Among NRTI DRMs, M184IV was the most prevalent (n = 36/104, 34.6%), followed by K65R (20/104, 19.2%) (Figure 1c).
Result: The main mutations found in the NRTI class were M184V (n = 4/11, 36.4%) associated with cytosine analogues and abacavir resistance, and the main TA mutation (TAM) T215S in its revertant form (n = 3/11, 27.3%).
Discussion: Finally, while the tenofovir-selected mutation K65R confers significant resistance to tenofovir and abacavir, its combination with M184IV actually increases the level of resistance to abacavir, but decreases resistance to tenofovir.
Discussion: Moreover, the detection of TAMs, likely resulting from prior use of TAs, can enhance the resi
In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2.
Abstract: With one exception, all resistant viruses had canonical nucleoside reverse transcriptase inhibitors (NRTIs)-associated resistance mutations (K65R, N69S, V111I, Y115F, Q151M and M184V).
Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa.
PMID: 30430843
2019
AIDS research and human retroviruses
Abstract: The most prevalent SDRMs were K103NS (7.5%), M184VI (2.4%), and V106AM (1.4%).
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
PMID: 30476165
2019
The Journal of antimicrobial chemotherapy
Abstract: Neither M184V nor integrase resistance mutations were detected after failure or blips.
HIV mutation literature information.
PMID: 
2020
Journal of the Pediatric Infectious Diseases Society
Browser Board
Co-occurred Entities
Filtrator
ViMRT